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Introduction {#sec001}
============

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia was prevalent in China from December 2019 to March 2020 and is currently being controlled effectively. However, SARS-CoV-2 cases are still rapidly increasing in other countries, representing a significant threat to global health \[[@pone.0236858.ref001]--[@pone.0236858.ref006]\]. SARS-CoV-2 is highly contagious and may lead to acute respiratory distress or multiple organ failure \[[@pone.0236858.ref007], [@pone.0236858.ref008]\]. In SARS-CoV-2 pneumonia, chest computed tomography (CT) plays a key role in the diagnosis and evaluation of lesions \[[@pone.0236858.ref009], [@pone.0236858.ref010]\]. Previous studies described the shape, distribution and CT score of lesions and demonstrated diverse and rapidly changing chest CT manifestations of SARS-CoV-2 pneumonia \[[@pone.0236858.ref011]--[@pone.0236858.ref014]\]. These studies also reported ground-glass opacity (GGO) and consolidation lesions as two main features \[[@pone.0236858.ref015]--[@pone.0236858.ref018]\]. However, few studies on quantitative lung lesion features and temporal changes of SARS-CoV-2 pneumonia have been reported. Recently, artificial intelligence (AI) has demonstrated great success in the medical imaging domain due to its feature extraction ability, and this technique automatically classifies typical interstitial pneumonia using regional volumetric texture analysis in high-resolution CT \[[@pone.0236858.ref019], [@pone.0236858.ref020]\], representing a new paradigm for precisely describing the severity of SARS-CoV-2 pneumonia. Thus, we aimed to describe the evolution of quantitative lung lesion features in both severe and common SARS-CoV-2 pneumonia using an AI system with high-resolution CT imaging. We hope that our findings will help physicians objectively estimate temporal changes in the percentage of lung lesion volume in common and severe SARS-CoV-2 pneumonia patients.

Materials and methods {#sec002}
=====================

The Ethics of Committees of the First Affiliated Hospital of Nanchang University approved this study. Informed consent was waived for this retrospective study. Data were collected and analyzed anonymously.

Participants {#sec003}
------------

In this study, records for patients diagnosed with SARS-CoV-2 pneumonia were reviewed retrospectively from 24 January 2020 to 15 March 2020. Patients were diagnosed according to the preliminary diagnosis and treatment protocols from the National Health Commission of the People's Republic of China \[[@pone.0236858.ref021]\]. Confirmed patients were eligible if they were admitted within 7 days from onset of initial symptoms and underwent an initial chest CT examination. The exclusion criteria were as follows: (1) patients with no obvious abnormal CT findings (mild type pneumonia), (2) patients who developed critical pneumonia because they were reviewed by a bedside chest X-ray rather than a chest CT. Finally, patients in this study were classified into the common and severe group according to the diagnostic criteria of severe pneumonia \[[@pone.0236858.ref021]\].

CT protocol {#sec004}
-----------

Noncontrast chest CT scans were performed using a single inspiratory phase with commercial multi-detector CT scanners (Philips Brilliance iCT, Philips Medical Systems, the Netherlands). CT images were acquired at end inspiration. The scans were reconstructed as axial images with a slice thickness of 1--1.5 mm (iDose 4, Philips Medical Systems, the Netherlands). Image analysis was performed using Radiology Information System/Picture Archiving and Communication System.

Chest CT evaluation {#sec005}
-------------------

In this study, the Intelligent Evaluation System for Novel Coronavirus Pneumonia (version 6.5, Hangzhou YITU Healthcare Technology Co., Ltd.) was employed as the thin-section image analysis tool. The system combined the convolutional neural network and thresholding methods for segmentation of left and right lungs and detection of patchy shadows. Based on threshold CT values in the pneumonia lesions, quantitative CT features of pneumonia lesions were automatically calculated using artificial intelligence algorithms, including the percentages of lesion volume with ranges of -700\~-500 Hounsfield units (HU), -500\~60 HU, and -700\~60 HU, representing the percentages of ground-glass opacity volume (PGV), consolidation volume (PCV) and total pneumonia lesion volume (PTV) in both lungs ([S1 Fig](#pone.0236858.s001){ref-type="supplementary-material"}). Normal lungs were defined with range of -1000\~-700 HU. The distribution of CT values in lungs was calculated to obtain a histogram. Based on this, the software outlined various lesions in each layer of the scanned images, then acquired the volume of lesions by calculating the pixels of each area outlined. Radiologists (WL and GHH) discerned and recorded PGV, PCV and PTV values.

Statistical analysis {#sec006}
--------------------

Statistical analyses were performed using IBM SPSS Statistics Software (version 21; IBM, New York, USA) and R software (version 3.0; Statistical Computing c/o Institute, Vienna, Austria) (<http://www.r-project.org/>). Quantitative data were presented as the mean ± standard deviation (minimum-maximum) or median (quartiles). The counting data were presented as the percentage of the total. PGV, PCV and PTV as a function of time were assessed and graphed by using the curve estimation module from package of "ggplot" of R software. Comparisons of nonpaired and paired quantitative data were evaluated using the Mann-Whitney U test and Wilcoxon test according to the normal distribution of data as assessed by the Shapiro-Wilk test. An exact *p* value was used due to the insufficient sample size, and a *p* value of \< 0.05 was defined as statistically significant.

Results {#sec007}
=======

Patient characteristics {#sec008}
-----------------------

A total of 73 patients were included in the study ([Table 1](#pone.0236858.t001){ref-type="table"}), including 53 cases of common pneumonia and 20 cases of severe pneumonia. The average age was 45 ± 14 years for patients with common pneumonia and 50 ± 15 years for patients with severe pneumonia. The median time of the first pulmonary CT scan obtained from the onset of symptoms was 4 days (quartiles = 2, 6 days) for common pneumonia and 5 days (quartiles = 2.25, 6 days) in severe pneumonia. Half of the patients with severe pneumonia exhibit comorbidities. The most common comorbidities were hypertension (11.3%) and hepatitis B (13.2%) for common pneumonia and diabetes (30%) and hypertension (30%) for severe pneumonia. The most prevalent presenting symptoms were fever (88.7% in common pneumonia, 95% in severe pneumonia) and cough (45.3% in common pneumonia, 60% in severe pneumonia) ([Table 1](#pone.0236858.t001){ref-type="table"}).

10.1371/journal.pone.0236858.t001

###### Characteristics of patients with common and severe SARS-CoV-2 pneumonia.

![](pone.0236858.t001){#pone.0236858.t001g}

                                                                        Common             Severe
  --------------------------------------------------------------------- ------------------ ------------------
  **Patient demographics**                                                                 
  Age, years, mean ± SD (min, max)                                      45 ± 14 (17, 75)   50 ± 15 (21, 83)
  Sex, No. (%)                                                                             
  Male                                                                  31 (58.5)          11 (55.0)
  Female                                                                22 (41.5)          9 (45.0)
  Interval time of first CT scan from onset, days, Median (Quartiles)   4 (2, 6)           5 (2.25, 6)
  **Comorbid conditions, No. (%)**                                                         
  Any                                                                   16 (32.2)          10 (50.0)
  Diabetes Mellitus                                                     5 (9.4)            6 (30.0)
  High Blood Pressure                                                   6 (11.3)           6 (30.0)
  Hepatitis B                                                           7 (13.2)           4 (20.0)
  Others                                                                2 (3.8)            1 (5.0)
  **Initial signs and symptoms, No. (%)**                                                  
  Fever                                                                 47 (88.7)          19 (95.0)
  Cough                                                                 24 (45.3)          12 (60.0)
  Sputum production                                                     7 (13.2)           4 (20)
  Fatigue weakness                                                      8 (15.1)           4 (20)
  Myalgia                                                               3 (5.7)            2 (10)
  Sore throat                                                           6 (11.3)           3 (15)
  Headache                                                              10 (18.9)          1 (5.0)
  Chills                                                                9 (17.0)           2 (10.0)
  Diarrhea                                                              1 (1.9)            1 (5.0)
  Nausea                                                                1 (1.9)            1 (5.0)
  Vomit                                                                 1 (1.9)            1 (5.0)

Quantitative data are presented as the mean ± standard deviation (minimum-maximum) or median (quartiles range). The counting data are presented as the percentage of the total. No., numbers; CT, computed tomography.

Pulmonary CT evaluation {#sec009}
-----------------------

In common pneumonia, the PTV increased slowly, peaked approximately 12 days after the onset of initial symptoms with the peak percentage ranging from 2.5 to 5%, and then gradually decreased ([Fig 1](#pone.0236858.g001){ref-type="fig"}). In severe pneumonia patients, the PTV rapidly increased and peaked approximately 17 days after the onset of initial symptoms with the peak percentage ranging from 22 to 25% ([Fig 1](#pone.0236858.g001){ref-type="fig"}). The temporal trends of PGV and PCV were generally consistent with PTV in both groups.

![Changes in PTV, PCV and PTV on chest CT from time of onset of initial symptoms (days).\
Temporal changes in PTV (a), PGV (b) and PCV (c) for each patient. Fitted curve is depicted in each graph. PGV, percentage of ground-glass opacity volume; PCV, percentage of consolidation volume; PTV, percentage of total pneumonia lesion volume.](pone.0236858.g001){#pone.0236858.g001}

Five stages were identified from the onset of initial symptoms: Stage 1 (0--3 days), Stage 2 (4--7 days), Stage 3 (8--14 days), Stage 4 (15--21 days), and Stage 5 (22--30 days). In Stage 1, PTV, PGV and PCV were not significantly different between the two types of pneumonia. In Stage 2, the severe group exhibited significantly increased PTV, PGV and PCV compared with the common group (*p =* 0.001 for PTV, *p =* 0.001 for PGV and *p =* 0.001 for PCV). The difference persisted through Stages 3, 4 and 5 (*p \<* 0.05) ([Table 2](#pone.0236858.t002){ref-type="table"}).

10.1371/journal.pone.0236858.t002

###### Comparison of PTV, PGV and PCV between common and severe SARS-CoV-2 pneumonia among five stages.
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                     Stage 1 (0--3 days)   Stage 2 (4--7 days)   Stage 3 (8--14 days)   Stage 4 (15--21 days)   Stage 5 (22--30 days)                                                                                                                                
  ------------------ --------------------- --------------------- ---------------------- ----------------------- ----------------------- ------- ------------ ---------------- --------- ---------------- ------------------ --------- ------------ ----------------- ---------
  **Lesions, (%)**                                                                                                                                                                                                                                                   
  PTV                4 (2, 8)              2 (0, 5)              0.223                  3 (2, 7)                14.5 (5.5, 20.25)       0.001   4 (1, 9)     21 (14, 29)      \<0.001   5.5 (2, 10)      20 (8, 29.5)       \<0.001   1 (0, 4.5)   12.5 (5, 20.75)   \<0.001
  PGV                3 (1, 7)              1 (0, 5)              0.205                  2 (1, 5)                11.5 (4.5, 16)          0.001   3 (1, 6)     16 (10, 22.75)   \<0.001   5 (1.25, 8.75)   15.5 (7, 25.25)    \<0.001   1 (0, 3.5)   10.5 (4, 18.25)   \<0.001
  PCV                1 (0, 2)              0 (0, 1)              0.273                  1 (0, 1)                3.5 (1, 4)              0.001   1 (0, 2.5)   5.5 (1, 8)       \<0.001   1 (0, 2)         3.5 (1.25, 5.75)   0.001     0 (0, 0)     2 (0, 5)          \<0.001

Quantitative data were presented as median (quartiles range). A *p* value was calculated using the Mann-Whitney U test in this table. PGV, percentage of ground-glass opacity volume; PCV, percentage of consolidation volume; PTV, percentage of total pneumonia lesion volume.

In common pneumonia, no significantly differences in the PTV, PGV and PCV were noted between Stages 1 and Stage 2, Stages 2 and 3, as well as Stages 3 and 4. However, the percentage of lesions in Stage 5 was reduced compared with that in Stage 4 (*p =* 0.002 for PTV, *p =* 0.003 for PGV and *p =* 0.001 for PCV) ([Table 3](#pone.0236858.t003){ref-type="table"}). In severe pneumonia patients, PTV, PGV and PCV began to increase from Stage 2 to Stage 4 and decreased in Stage 5. In the severe group, Stage-2 patients exhibited increased PTV, PGV and PCV compared with Stage-1 patients (*p =* 0.004 for PTV, *p =* 0.005 for PGV and *p =* 0.005 for PCV), and Stage-3 patients exhibited slightly increased PTV, PGV and PCV compared with Stage-2 patients (*p =* 0.048 for PTV, *p =* 0.036 for PGV and *p =* 0.056 for PCV). PTV and PGV were not significantly different between Stages 3 and 4 (*p =* 0.081 for PTV and *p =* 0.278 for PGV), whereas PCV was reduced from Stages 3 to 4 (*p =* 0.006). PTV, PGV and PCV in Stage 5 were reduced compared with that in Stage 4 (*p \<* 0.001 for PTV, *p =* 0.001 for PGV and *p =* 0.001 for PCV) ([Table 3](#pone.0236858.t003){ref-type="table"}).

10.1371/journal.pone.0236858.t003

###### Comparison of PTV, PGV and PCV between stages.
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                         Stage 1 vs. Stage 2 *p* value   Stage 2 vs. Stage 3 *p* value   Stage 3 vs. Stage 4 *p* value   Stage 4 vs. Stage 5 *p* value
  ---------------------- ------------------------------- ------------------------------- ------------------------------- -------------------------------
  **Common pneumonia**                                                                                                   
  PTV                    0.963                           0.996                           0.746                           0.002
  PGV                    0.846                           0.676                           0.527                           0.003
  PCV                    1                               0.915                           0.909                           0.001
  **Severe pneumonia**                                                                                                   
  PTV                    0.004                           0.048                           0.081                           \<0.001
  PGV                    0.005                           0.036                           0.278                           0.001
  PCV                    0.005                           0.056                           0.006                           0.001

Wilcoxon test was used in the comparisons between Stages 3 and 4 as well as between Stages 4 and 5 in patients with severe pneumonia. Mann-Whitney U test was used for other comparisons in this table. Please refer to [Table 2](#pone.0236858.t002){ref-type="table"} for quantitative data of variables of each group. PGV, percentage of ground-glass opacity volume; PCV, percentage of consolidation volume; PTV, percentage of total pneumonia lesion volume.

Discussion {#sec010}
==========

In this study, we provided reliable data of the temporal and lesion-quantified patterns for both types of SARS-CoV-2 pneumonia. Severe pneumonia exhibited greater PTV, PGV and PCV than common pneumonia, and these features appeared in Stage 2 (4--7 days from onset of initial symptoms) and remained in all subsequent stages. Severe pneumonia exhibited later peak and recovery time of PTV, PGV and PCV compared with common pneumonia.

Our results showed greater PTV, PGV and PCV in patients with severe pneumonia than in those with common pneumonia, demonstrating the close relationship between the extent of lung lesion involvement and pneumonia severity. This finding is consistent with previous results demonstrating that patients with severe SARS-CoV-2 pneumonia were more likely to exhibit increased involvement of GGO and consolidation lesions compared with patients with common SARS-CoV-2 pneumonia \[[@pone.0236858.ref022]\]. In this study, quantitative lung lesion features in SARS-CoV-2 pneumonia might provide a more accurate and objective description of the involvement of lesions compared with previous studies with nonquantifiable patterns. Moreover, we also found increased PTV, PGV and PCV in severe pneumonia patients at Stage 2 (4--7 days from onset of initial symptoms) compared with common patients. As a result, we hypothesized that lung lesion involvement in Stage 2 but not Stage 1 might represent a valuable marker to predict the severity of SARS-CoV-2 pneumonia.

In the severe group, PCV declined significantly from Stage 3 to Stage 4, whereas PGV and PTV were not reduced. During this stage, the density (Hounsfield Unit) of consolidation decreased due to lesion absorption, which resulted in a portion of the consolidation lesion developing into a GGO lesion. Thus, we hypothesized this process might explain why PGV and PTV were not significantly reduced. Thus, in the period from Stage 3 to Stage 4, lesions are absorbed slightly.

The limitations of this study include the lack of chest CT scans in Stage-4 (n = 32) or Stage-5 (n = 37) common pneumonia patients compared with Stage-3 (n = 53) patients. The lack of chest CT scans resulted in inaccurate assessment of lesion changes from Stage 3 to Stage 4. It is possible that some Stage-1 to Stage-3 patients showed mild symptoms and a low percentage of lesions, so these patients did not receive close medical observation.

Conclusions {#sec011}
===========

In conclusion, increased PTV, PGV and PCV are noted in severe SARS-CoV-2 pneumonia patients beginning at Stage 2 (4--7 days after the onset of initial symptoms) compared with common SARS-CoV-2 pneumonia patients. Patients with severe pneumonia exhibited increased PTV, PGV and PCV as well as later peak time of lesion percentage and recovery time compared with patients with common SARS-CoV-2 pneumonia. Quantitative lung lesion features in SARS-CoV-2 pneumonia can objectively describe temporal changes in the percentage of pneumonia lesions.

Supporting information {#sec012}
======================

###### Schematic diagram of AI calculation method for PGV, PCV and PTV.

(DOCX)

###### 

Click here for additional data file.
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Dear reviewers，

Thank you very much for your guidance and advice. Here are the responses for your specific points.

1\. For paired comparisons, there are quite a few of them and so there needs to be some correction of the level of significance to account for this large number of comparisons

Re: Thank you for your comments. It is a very valuable advice. The question is also the limit in the study for not every patient included underwent CT scan in each stage. We have made a statistical analysis of all the data, and we use the exact p value to replace the p value in Mann-both Whitney U test and Wilcoxon test.

2\. Some of the p-values are much smaller than expected. For example, for severe disease, the total lung opacities for stage 3 was 21% (interquartile 14, 29) and for stage 4 was 20% (interquartile 8, 29.5), meaning that there was quite a big standard deviation and nearly identical median values. Further, the sample size n was only 20, yet the p-value comparison for stage 3 and 4 was a shockingly low 0.08, which is impossibly small for such data. Similarly the finding of consolidation was 5.5% with interquartile range 1, 8 for Stage 3 and was 3.5 with interquartile range 1.25, 5.75 for Stage 4 for severe disease, which with an n=20 should not yield a particularly significant p-value, but here is reported as p=0.003 which is surprisingly significant.

Re: Thank you for your comments. These two sets of comparative data have been checked and analyzed repeatedly, and the p value in previous edition has been also replaced by the exact p value, but it has little change. We tried to analyze the comparisons by Mann-Whitney U test rather than paired comparisons, the p value was shockingly increased. Thus, we think that shockingly ow or particularly significant p value is because these two comparisons are paired tests.

3\. The manuscript needs to use precise terms that are defined clearly. Line 89, the "proportion of inflammatory volume" should probably be "percent lung volume involved by pathological opacity" or some other more specific term that includes the unit of measure. Oddly, the term "proportion of inflammatory volume" is never used again in the manuscript except fig 1. Instead the undefined ambiguous term "percentage of lung lesions" is used. What does "percentage of lung lesions"mean? Is it the percent of the diseased lung that is GGO? The total volume of the lung that is pathological in HU value? Please define.

Re: Thank you for your comments. We are very sorry to confuse you by the inconsistent and ambiguous terms in our manuscript on lesion percentage. In previous version, both "proportion of inflammatory volume" and "percentage of lung lesions" mean "percentage of total lesion volume". We have substituted these inconsistent terms by "the percentages of ground-glass opacity volume (PGV)", "the percentages of consolidation volume (PCV)", and the percentages of the total lesions volume (PTV)" in both lungs. The percentage of total lesions volume was defined with ranges of -700\~-500 Hounsfield units (HU), that is, the sum area of both PGV and PCV.

4\. The HU ranges for normal versus GGO versus consolidation should be described -- was it the same for all patients? Was it normalized or adjusted in any way for each patient? How exactly does the software assign the \"proportion of inflammatory volume\"?

Re: Firstly, we have added it in the Material and Methods that percentages of lesion volume with ranges of -700\~-500 Hounsfield units (HU), -500\~60 HU, and -700\~60 HU corresponded to percentages of ground glass opacity volume (PGV), consolidation volume (PCV) and total lesion volume (PTV), where total lesion volume was defined as the sum area of both PGV and PCV. The normal lung was defined with range of -1000\~-700 HU. Secondly, data calculation method was the same for all patients. All patients with SARS-CoV-2 pneumonia were performed with the same CT scanner and the same scanning parameters. The data were also processed with the same software analysis parameters to ensure the consistency of these data. Thirdly, the software assigned the \"proportion of inflammatory volume\" by outlining the lesions in each layer of the scanned images, then acquired the volume of the lesions by calculating the pixels of each area outlined. The process also has been added in the Material and Methods.

5\. In the results, the term "percentage of lesions" is ambiguous and should be replaced by a more understandable term throughout the manuscript. Does it mean "lung volume percentage involved by pathological lung opacity" or is it just lung volume percentage involved by GGO or lung volume percentage involved by consolidation? The figures also use different terms. Fig 1 uses one term while Fig 2 uses the term "percentage of lung involvement" which is different than the terms used elsewhere in the text.

Re: We are very sorry to confuse you by the inconsistent and ambiguous terms in our manuscript on lesion percentage. In previous version, percentage of lesions represented different means according to the conjunctions, eg. percentage of lesions of GGO or percentage of lesions of consolidation. Sometimes we omitted the conjunctions so that some confusion was produced. Thus, we have substituted these inconsistent terms by "the percentages of ground-glass opacity volume (PGV)", "the percentages of consolidation volume (PCV)", and the percentages of the total lesions volume (PTV)" in both lungs.

6\. The Y-axis of the figures needs to be the same between the three graphs (total, GGO, and consolidation). Having different y-axis makes it hard to compare.

Re: Thank you for your comments. We have made the Y-axis of the figures the same between the three graphs (total, GGO, and consolidation). The modified figure has been uploaded.

If you have any questions, please let me know. Look forward to your response.

Sincerely yours

###### 

Submitted filename: Response to reviewers.docx

###### 

Click here for additional data file.
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Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.
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